Soleno Therapeutics to Participate in Upcoming February Investor Conferences
Soleno Therapeutics (NASDAQ: SLNO), a clinical-stage biopharmaceutical company focused on rare disease therapeutics, has announced its participation in two major investor conferences this February. The company will present at the Guggenheim SMID Cap Biotech Conference on February 6, 2025, at 2:00 PM ET in a fireside chat format, and at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025, at 2:40 PM ET as a corporate presentation.
Both presentations will be available via webcast, with replay options accessible through the Investors section of Soleno's website at www.soleno.life.
Soleno Therapeutics (NASDAQ: SLNO), un'azienda biofarmaceutica in fase clinica focalizzata sui farmaci per malattie rare, ha annunciato la sua partecipazione a due importanti conferenze per investitori questo febbraio. L'azienda presenterà alla Guggenheim SMID Cap Biotech Conference il 6 febbraio 2025, alle 14:00 ET, in un formato di conversazione informale, e all'Oppenheimer 35th Annual Healthcare Life Sciences Conference l'11 febbraio 2025, alle 14:40 ET, con una presentazione aziendale.
Entrambe le presentazioni saranno disponibili tramite webcast, con opzioni di replay accessibili nella sezione Investitori del sito web di Soleno all'indirizzo www.soleno.life.
Soleno Therapeutics (NASDAQ: SLNO), una compañía biofarmacéutica en etapa clínica centrada en terapias para enfermedades raras, ha anunciado su participación en dos importantes conferencias para inversores este febrero. La empresa presentará en la Guggenheim SMID Cap Biotech Conference el 6 de febrero de 2025, a las 2:00 PM ET en un formato de conversación informal, y en la Oppenheimer 35th Annual Healthcare Life Sciences Conference el 11 de febrero de 2025, a las 2:40 PM ET como una presentación corporativa.
Ambas presentaciones estarán disponibles a través de webcast, con opciones de repetición accesibles a través de la sección de Inversores del sitio web de Soleno en www.soleno.life.
솔레노 테라퓨틱스(SNASDAQ: SLNO), 희귀 질환 치료제에 집중하는 임상 단계의 생명공학 회사,가 이번 2월 두 개의 주요 투자자 컨퍼런스에 참여한다고 발표했습니다. 이 회사는 구겐하임 SMID 캡 바이오테크 컨퍼런스에서 2025년 2월 6일 오후 2시(동부 표준시)에 대화 형식으로 발표할 예정이며, 오펜하이머 제35회 연례 헬스케어 생명과학 컨퍼런스에서 2025년 2월 11일 오후 2시 40분(동부 표준시)에 기업 발표를 진행할 것입니다.
두 발표 모두 웹캐스트를 통해 제공되며, 솔레노 웹사이트의 투자자 섹션에서 재생 옵션을 통해 접근할 수 있습니다: www.soleno.life.
Soleno Therapeutics (NASDAQ: SLNO), une entreprise biopharmaceutique en phase clinique axée sur les thérapies pour les maladies rares, a annoncé sa participation à deux grandes conférences pour investisseurs en février. L'entreprise présentera à la Guggenheim SMID Cap Biotech Conference le 6 février 2025 à 14h00 ET dans un format de discussion informelle, et à la Oppenheimer 35th Annual Healthcare Life Sciences Conference le 11 février 2025 à 14h40 ET sous forme de présentation d'entreprise.
Les deux présentations seront disponibles par webcast, avec des options de rediffusion accessibles via la section Investisseurs du site Web de Soleno à www.soleno.life.
Soleno Therapeutics (NASDAQ: SLNO), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf Therapeutika für seltene Krankheiten konzentriert, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im Februar bekannt gegeben. Das Unternehmen wird am Guggenheim SMID Cap Biotech Conference am 6. Februar 2025 um 14:00 Uhr ET in einem informellen Gesprächsformat präsentieren und am Oppenheimer 35th Annual Healthcare Life Sciences Conference am 11. Februar 2025 um 14:40 Uhr ET einen Unternehmensvortrag halten.
Beide Präsentationen werden über Webcast zur Verfügung stehen, mit Replay-Optionen, die über den Bereich Investoren auf der Soleno-Website unter www.soleno.life zugänglich sind.
- None.
- None.
REDWOOD CITY, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in February:
Guggenheim SMID Cap Biotech Conference
Presentation Date: Thursday, February 6, 2025 at 2:00 PM ET
Presentation Format: Fireside Chat
Webcast: https://wsw.com/webcast/guggen2/slno/2028708
Oppenheimer 35th Annual Healthcare Life Sciences Conference
Presentation Date: Tuesday, February 11, 2025 at 2:40 PM ET
Presentation Format: Corporate Presentation
Webcast: https://wsw.com/webcast/oppenheimer39/slno/2814816
A replay of both events will be available in the Investors section on the Company’s website at www.soleno.life.
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. An NDA for its lead candidate, DCCR (diazoxide choline) extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS) is currently under review by the FDA and was granted Priority Review. For more information, please visit www.soleno.life.
Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
FAQ
When is Soleno Therapeutics (SLNO) presenting at the Guggenheim SMID Cap Biotech Conference?
What type of presentation will SLNO deliver at the Oppenheimer Healthcare Conference?
How can investors access the webcasts of SLNO's February 2025 conference presentations?
What is the timing of SLNO's presentation at the Oppenheimer Conference in February 2025?
Which investor conferences is SLNO participating in during February 2025?
